NCT05376579 - Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Active Secondary Progressive Multiple Sclerosis

Interventions

OTHER

siponimod

Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.

Trial Locations (24)

10043

Novartis Investigative Site, Orbassano

16132

Novartis Investigative Site, Genova

20133

Novartis Investigative Site, Milan

22100

Novartis Investigative Site, Como

24127

Novartis Investigative Site, Bergamo

25123

Novartis Investigative Site, Brescia

27100

Novartis Investigative Site, Pavia

28100

Novartis Investigative Site, Novara

34149

Novartis Investigative Site, Trieste

35128

Novartis Investigative Site, Padua

36100

Novartis Investigative Site, Vicenza

40139

Novartis Investigative Site, Bologna

56124

Novartis Investigative Site, Pisa

60126

Novartis Investigative Site, Ancona

67100

Novartis Investigative Site, L’Aquila

71122

Novartis Investigative Site, Foggia

80132

Novartis Investigative Site, Napoli

80138

Novartis Investigative Site, Napoli

88100

Novartis Investigative Site, Catanzaro

90127

Novartis Investigative Site, Palermo

98121

Novartis Investigative Site, Messina

00133

Novartis Investigative Site, Roma

00152

Novartis Investigative Site, Roma

00189

Novartis Investigative Site, Roma